Redhill Biopharma
RDHL
18 hedge funds and large institutions have $419K invested in Redhill Biopharma in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
13% more funds holding
Funds holding: 16 → 18 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
65% less capital invested
Capital invested by funds: $1.2M → $419K (-$782K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$664K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$30.3K |
| 4 |
MOS
MGO One Seven
Beachwood,
Ohio
|
+$24.8K |
| 5 |
VF
Virtu Financial
New York
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.06M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$93K |
| 3 |
Barclays
London,
United Kingdom
|
-$5.21K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.65K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$922 |
RDHL Hedge Fund Activity: Q2 2023 in Review
18 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2023, worth a combined $419K — down 65% from $1.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RDHL positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $664K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.06M sold.
- 18 institutional investors held Redhill Biopharma (RDHL) as of Q2 2023, up from 16 in Q1 2023.
- Funds reported $419K of Redhill Biopharma stock for Q2 2023, down 65% quarter-over-quarter.
- 7 funds opened new Redhill Biopharma positions in Q2 2023 and 5 closed out, a net change of +2 holders.
- The largest Redhill Biopharma buyer in Q2 2023 was Cowen and Company, an estimated $664K added.
- The largest Redhill Biopharma seller in Q2 2023 was Armistice Capital, an estimated $1.06M sold.
Based on aggregated 13F filings for Q2 2023.